磁振造影(Magnetic Resonance Imaging, MRI)檢查提供子宫頸癌患者在分期和追蹤上有明確指標，故介紹了 國際聯邦婦產科癌症分期系統(International Federation of Gynecology and Obstetrics, FIGO)、磁振造影檢查和治療 方式三者的關聯。通常子宫頸癌分期在IA以下的腫瘤，在MRI影像上是看不到的，低於IIA以下，除了腫瘤直 徑>4cm(IB或IIA)，都是利用外科手術的治療方式，分期IIB、IIB以上或腫瘤直徑>4cm的子宫頸癌，則是利用 放射治療或結合化學治療的治療方式來處理。分期的正確與否，直接影響了整個治療的方向、策略和選擇，在子 宫頸癌方面，MRI不論在腫瘤大小、子宫肌層、子宫附近、骨盆側壁、器官侵犯，或是淋巴轉移等，是比電腦斷 層(CT)的檢查具有更高的對比解析度，而且不具輻射線，希望能為子宫頸癌患者的治療策略和預後追蹤，提供一 項重要的辨別檢查。

In order to provide a clear indication of the stage and tracking of cervical cancer patients by magnetic resonance imaging (MRI), the association between FIGO (International Federal Obstetrics and Gynecology Cancer Staging System), magnetic resonance imaging and treatment methods is introduced. Tumors with a stage of cervical cancer below IA are generally invisible on MRI images, below IIA, except for tumors > 4 cm (IB or IIA), which are surgically treated. Cervical cancer with a stage IIB, IIB or above or a tumor diameter >4 cm is treated by radiotherapy or a combination of chemotherapy. The correctness of the staging directly affects the direction, strategy and choice of the whole treatment. In cervical cancer, MRI is in the size of the tumor, myometrium, uterus, pelvic wall, organ invasion, or lymphatic metastasis. Compared with computed tomography (CT) examination, it has a higher contrast resolution and no radiation. It is hoped to provide an important discriminating test for the treatment strategy and prognosis of cervical cancer patients.